Modern Slavery Act Transparency Statement (Fiscal 2024)

This statement has been published in accordance with section 54 of the UK Modern Slavery Act 2015 and constitutes the modern slavery and human trafficking statement for Haemonetics Limited and Haemonetics S.A. for the fiscal 2024 period (i.e., April 2, 2023 to March 30, 2024).

Haemonetics Limited and Haemonetics S.A. are all subsidiaries of Haemonetics Corporation, a Massachusetts corporation. References to “Haemonetics”, the “Company”, “we”, “us” or “our” refer to Haemonetics Corporation and its subsidiaries as a whole unless otherwise stated.

Introduction

Haemonetics is committed to high standards in ethical conduct and the prevention of modern slavery and human trafficking in its business and supply chains. Haemonetics will not tolerate or condone such human trafficking or slavery in any part of our global organization and our suppliers are expected to comply with the guidelines set forth in our Global Anti-Human Trafficking Policy that prohibit such activities.

Haemonetics is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. We view our operations and manage our business in three principal reporting segments: Plasma, Blood Center and Hospital.

Haemonetics conducted business in approximately 90 countries and had distributors in approximately 80 of these countries during fiscal 2024. As of March 30, 2024, we employed the full-time equivalent of 3,657 persons globally, with approximately 82% of our employees located in North America and the remaining 18% located across 19 other countries. As of March 30, 2024, our principal manufacturing centers were located in Pennsylvania and California within the U.S., as well as internationally in Mexico and Malaysia, and our products were distributed worldwide from primary distribution centers in the United States, Europe as well as smaller locations globally.

In general we design our equipment and consumables and use contract manufacturers to build the devices, while the majority of consumables are manufactured by us. Haemonetics has acomplex global supply chain that involves integrating key suppliers and our manufacturing capacity into a global movement of components and finished goods.

Haemonetics Corporation is headquartered in Boston, MA (USA) and is publicly listed on the New York Stock Exchange. Contact information for our global offices is available on our website at www.haemonetics.com.

We are committed to upholding the laws and regulations that apply to our products and services around the world and will not tolerate or condone human trafficking or slavery in any part of our global organization. Haemonetics maintains several policies and practices that reinforce this commitment across our organization, including:

Haemonetics’ Code of Conduct is a manifestation of the values that unite us across our business globally. We expect our suppliers to share our commitment to the same high ethical standards and to follow our Code of Conduct.

Haemonetics’ Expectations for Suppliers statement reinforces specific expectations for Haemonetics suppliers, including compliance with the guidelines set forth in our Global Anti- Human Trafficking Policy. Haemonetics seeks to partner with suppliers who operate in a manner consistent with these expectations and to support our suppliers in understanding and conforming with them. Haemonetics may take steps to assess a supplier’s conformance with these expectations and will consider a supplier’s progress in meeting these expectations in its sourcing decisions.

Due Diligence Processes

For our own operations, including our manufacturing and distribution facilities, Haemonetics maintains programs and procedures that foster a culture of compliance with our Code, our Global Anti-Human Trafficking Policy and the law. We conduct due diligence on all third-party distributors which involves reputational background checks and screenings to assess, among other things, the distributor’s efforts to assure that human trafficking and slavery do not exist in its operations. Within our supply chain, Haemonetics targets completion of quality audits (either in person or virtually) of approximately one third of our direct suppliers annually. We recognize that our highest risk distributors and suppliers for purposes of human trafficking and slavery are likely to be found in countries and industries cited for having the highest prevalence of modern slavery and human trafficking violations.

All employees are required to complete annual online training on our Code of Conduct, which includes a standalone module on human trafficking and slavery. The training module defines modern slavery and human trafficking, identifies potential warning signs and articulates ways employees can help combat modern slavery and human trafficking and report suspected violations in accordance with Haemonetics’ Code of Conduct and Global Anti-Human Trafficking Policy. For our global distributors, Haemonetics periodically conducts trainings that address their obligation generally to comply with our Code of Conduct. Additionally, we began rollout of our Expectations for Suppliers statement in fiscal 2022 and have taken steps subsequently to incorporate it into our supplier reviewed processes.

Haemonetics remains committed to continually improving our policies and practices related to human trafficking and slavery. This commitment includes periodic reviews of our policies and practices and adoption of relevant key performance indicators within our organization.

In fiscal 2024 we maintained key performance indicators under which we would:

In April 2023, we published our first Corporate Responsibility Report. This inaugural Corporate Responsibility Report serves as a foundation on which we plan to build. We will continue to operate with transparency and report our progress as we take additional actions and set sustainability goals that advance our commitment to Corporate Responsibility and support our Purpose as we help customers to continue to make it matter.

We will also continue to monitor changes to applicable laws and regulations concerning human trafficking and slavery and evaluate corresponding changes to our current policies and practices.

This modern slavery and human trafficking statement has been approved by the boards of directors of Haemonetics Limited and Haemonetics S.A. for the fiscal 2024 period ended March 30, 2024.

/s/ James C. D’Arecca

Member of Board of Directors of Haemonetics Limited and Haemonetics S.A.

Date: September 17, 2024